Rejected petition Call on Government to review over priced private essential medicine by pharmaceuticals
Review into the pricing of essential medications like Mounjaro.
The decision by Eli Lilly to exploit patients by increasing Mounjaro cost by 170% is short-sighted, and shameful. It risks undoing the progress patients have made and lead to increased strain on the NHS in the long term. Patients can see relapses in diabetes, obesity-related complications, and other chronic conditions that are far more expensive to treat than to prevent by the NHS. It is not a luxury drug, it’s a lifeline.
More details
Expand NHS eligibility criteria for Mounjaro to include patients with mobility conditions who are currently excluded,
Introduce safeguards to prevent pharmaceutical companies from exploiting patients
Why was this petition rejected?
It’s about something that the Senedd or Welsh Government is not responsible for.
Petitions to the Senedd must call for a specific action that falls within the powers of the Senedd or Welsh Government.
Schedules 7A and 7B of the Government of Wales Act 2006 set out the issues which are ‘restricted’ or ‘reserved’ to the UK Parliament - i.e. areas where only the UK Parliament or Government, not the Senedd or Welsh Government, can act.
Under section J4 of Schedule 7A - Medicines, medical supplies, biological substances etc - including regulation of prices of medicinal products - is a reserved matter.
You may wish to consider petitioning the UK Parliament about this issue instead: https://petition.parliament.uk/
We only reject petitions that don’t meet the petition standards
Rejected petitions are published in the language in which they were submitted